- Spectral Medical Inc. (EDT) has retained Crescendo Communications, LLC as its investor relations firm in the U.S.
- Crescendo’s prime mandate is to raise awareness of Spectral’s sepsis treatment products
- Spectral has obtained exclusive development and commercial rights in the U.S. for PMX, a therapeutic hemoperfusion device that removes endotoxin
- Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock
- Spectral Medical (EDT) is up 1.61 per cent, trading at C$0.63 per share at 2 pm EST
Spectral Medical (EDT) has retained Crescendo Communications, LLC to help raise awareness of Spectral’s sepsis treatment products in the U.S.
David Waldman, President and CEO of Crescendo, commented,
“We are honoured to work with Spectral and look forward to supporting them in their mission of combatting the devastating impacts of sepsis, a leading cause of death in ICUs across the U.S. Spectral’s Toraymyxin™ PMX endotoxin removal cartridge, combined with its EAA™ diagnostic, address a dramatically underserved $1.5 billion market opportunity with no competing FDA-approved solutions.
Additionally, we believe there is a significant market opportunity within the Dialco business, with two first-in-class hemodialysis machines, positioned to capture significant market share within the $5.3 billion acute and home dialysis markets. We look forward to helping increase awareness within the U.S. investment community, as Spectral advances towards a number of key milestones.”
PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the company’s Endotoxin Activity Assay (EAA™).
PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 200,000 patients to date.
In March 2009, Spectral obtained exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada.
Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.
Spectral is a Phase III company seeking U.S. FDA approval for Toraymyxin™ (“PMX”), its unique product for the treatment of patients with septic shock.
Spectral Medical (EDT) is up 1.61 per cent, trading at C$0.63 per share at 2 pm EST.
